trending Market Intelligence /marketintelligence/en/news-insights/trending/vbvw2pk07mik43ug1ijt3w2 content esgSubNav
In This List

Sosei beefs up board with R&D experts


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Sosei beefs up board with R&D experts

Sosei Group Corp. nominated Michael Hayden, Kuniaki Kaga and David Roblin as external directors to the company's board.

Hayden was previously global research and development president and chief scientific officer at Teva Pharmaceutical Industries Ltd.; Kaga was formerly senior managing executive officer at Mitsubishi Tanabe Pharma Corp.; and Roblin was formerly senior vice president, head of research and chief medical officer for Europe research and development at Pfizer Inc.

The Tokyo-listed biopharmaceutical company expects the new appointees to "provide experienced oversight" of the company's research and development pipeline among other services, the company said in a press release.

Meanwhile, Declan Doogan is retiring as an external director of the company.

The nominations have been submitted for approval at the company's shareholders meeting June 22.

Sosei develops and sells biopharmaceutical products internationally.